MicroRNA‑153 affects nasopharyngeal cancer cell viability by targeting TGF‑β2

Guo,Guangliang; Zhang,Ying; Hu,Limin; Bian,Xue

doi:10.3892/ol.2018.9570

MicroRNA‑153 affects nasopharyngeal cancer cell viability by targeting TGF‑β2

Authors:
- Guangliang Guo
- Ying Zhang
- Limin Hu
- Xue Bian
View Affiliations

Affiliations: Department of Otolaryngology, Beijing Royal Intergrative Medicine Hospital, Beijing 102209, P.R. China, Department of Otolaryngology Head and Neck Surgery, Beijing Army General Hospital, Beijing 100700, P.R. China
Published online on: October 12, 2018 https://doi.org/10.3892/ol.2018.9570
Pages: 646-651

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine the function of microRNA‑153 (miR‑153) in the viability of nasopharyngeal cancer (NPC) cells and determine the underlying molecular mechanism. The expression of miR‑153 in patients with NPC was markedly decreased compared with that in paracarcinoma tissue. miR‑153 upregulation observably decreased cell viability, induced apoptosis, increased caspase‑3 and ‑9 activity, and increased the B‑cell lymphoma 2 (Bcl‑2)‑associated X protein/Bcl‑2 protein expression ratio in 13‑9B cells. miR‑153 upregulation also suppressed transforming growth factor‑β2 (TGF‑β2) and Smad2 protein expression in 13‑9B cells. TGF‑β2 inhibitor enhanced the effect of miR‑153 upregulation on the inhibition of cell viability, induction of apoptosis, increase in caspase‑3 and ‑9 activity, and increase in Bax/Bcl‑2 protein expression ratio in 13‑9B cells. The results of the present study indicate that miR‑153 affects the progression of NPC by targeting the TGF‑β2/Smad2 signaling pathway.

View Figures

View References

1	Li Y, Pan K, Liu LZ, Li YQ, Gu MF, Zhang H, Shen WX, Xia JC and Li JJ: Sequential cytokine-induced killer cell immunotherapy enhances the efficacy of the gemcitabine plus cisplatin chemotherapy regimen for metastatic nasopharyngeal carcinoma. PLoS One. 10:e01306202015. View Article : Google Scholar : PubMed/NCBI
2	Lee FK, Yip CW, Cheung FC, Leung AK, Chau RM and Ngan RK: Dosimetric difference amongst 3 techniques: TomoTherapy, sliding-window intensity-modulated radiotherapy (IMRT), and RapidArc radiotherapy in the treatment of late-stage nasopharyngeal carcinoma (NPC). Med Dosim. 39:44–49. 2014. View Article : Google Scholar : PubMed/NCBI
3	Jiang H, Lu H, Yuan H, Huang H, Wei Y, Zhang Y and Liu X: Dosimetric benefits of placing dose constraints on the brachial plexus in patients with nasopharyngeal carcinoma receiving intensity-modulated radiation therapy: A comparative study. J Radiat Res. 56:114–121. 2015. View Article : Google Scholar : PubMed/NCBI
4	Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, Han J and Wu G: A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 104:286–293. 2012.
5	Liu N, Cui RX, Sun Y, Guo R, Mao YP, Tang LL, Jiang W, Liu X, Cheng YK, He QM, et al: A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma. Int J Cancer. 134:1359–1368. 2014. View Article : Google Scholar : PubMed/NCBI
6	Lung RW, Wang X, Tong JH, Chau SL, Lau KM, Cheng SH, Woo JK, Woo J, Leung PC, Ng MH, et al: A single nucleotide polymorphism in microRNA-146a is associated with the risk for nasopharyngeal carcinoma. Mol Carcinog. 52 (Suppl 1):E28–E38. 2013. View Article : Google Scholar : PubMed/NCBI
7	Spence T, Bruce J, Yip KW and Liu FF: MicroRNAs in nasopharyngeal carcinoma. Chin Clin Oncol. 5:172016. View Article : Google Scholar : PubMed/NCBI
8	Zhao L, Lin L, Pan C, Shi M, Liao Y, Bin J and Liao W: Flotillin-2 promotes nasopharyngeal carcinoma metastasis and is necessary for the epithelial-mesenchymal transition induced by transforming growth factor-β. Oncotarget. 6:9781–9793. 2015.PubMed/NCBI
9	Kan R, Shuen WH, Lung HL, Cheung AK, Dai W, Kwong DL, Ng WT, Lee AW, Yau CC, Ngan RK, et al: NF-κB p65 subunit is modulated by latent transforming growth factor-β binding protein 2 (LTBP2) in nasopharyngeal carcinoma HONE1 and HK1 cells. PLoS One. 10:e01272392015. View Article : Google Scholar : PubMed/NCBI
10	Zhang W, Zeng Z, Fan S, Wang J, Yang J, Zhou Y, Li X and Huang D: Evaluation of the prognostic value of TGF-β superfamily type I receptor and TGF-β type II receptor expression in nasopharyngeal carcinoma using high-throughput tissue microarrays. J Mol Histol. 43:297–306. 2012. View Article : Google Scholar : PubMed/NCBI
11	Chen WJ, Zhang EN, Zhong ZK, Jiang MZ, Yang XF, Zhou DM and Wang XW: MicroRNA-153 expression and prognosis in non-small cell lung cancer. Int J Clin Exp Pathol. 8:8671–8675. 2015.PubMed/NCBI
12	Wang W, Feng M, Fan Z, Li J and Lang J: Clinical outcomes and prognostic factors of 695 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Biomed Res Int. 2014:8149482014.PubMed/NCBI
13	Wang J, Zheng J, Tang T, Zhu F, Yao Y, Xu J, Wang AZ and Zhang L: A randomized pilot trial comparing position emission tomography (PET)-guided dose escalation radiotherapy to conventional radiotherapy in chemoradiotherapy treatment of locally advanced nasopharyngeal carcinoma. PLoS One. 10:e01240182015. View Article : Google Scholar : PubMed/NCBI
14	Long GX, Lin JW, Liu DB, Zhou XY, Yuan XL, Hu GY, Mei Q and Hu GQ: Single-arm, multi-centre phase II study of lobaplatin combined with docetaxel for recurrent and metastatic nasopharyngeal carcinoma patients. Oral Oncol. 50:717–720. 2014. View Article : Google Scholar : PubMed/NCBI
15	Bruce JP, Yip K, Bratman SV, Ito E and Liu FF: Nasopharyngeal cancer: Molecular landscape. J Clin Oncol. 33:3346–3355. 2015. View Article : Google Scholar : PubMed/NCBI
16	Zhu LH, Miao XT and Wang NY: Integrated miRNA-mRNA analysis of Epstein-Barr virus-positive nasopharyngeal carcinoma. Genet Mol Res. 14:6028–6036. 2015. View Article : Google Scholar : PubMed/NCBI
17	Low SY, Tan BS, Choo HL, Tiong KH, Khoo AS and Leong CO: Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells. Cancer Lett. 314:166–175. 2012. View Article : Google Scholar : PubMed/NCBI
18	Pan LL, Wang AY, Huang YQ, Luo Y and Ling M: Mangiferin induces apoptosis by regulating Bcl-2 and Bax expression in the CNE2 nasopharyngeal carcinoma cell line. Asian Pac J Cancer Prev. 15:7065–7068. 2014. View Article : Google Scholar : PubMed/NCBI
19	Li SS, Tang QL, Wang SH, Chen YH, Liu JJ and Yang XM: Simultaneously targeting Bcl-2 and Akt pathways reverses resistance of nasopharyngeal carcinoma to TRAIL synergistically. Tumori. 97:762–770. 2011. View Article : Google Scholar : PubMed/NCBI
20	Anaya-Ruiz M, Cebada J, Delgado-Lopez G, Sánchez-Vázquez ML and Pérez-Santos JL: miR-153 silencing induces apoptosis in the MDA-MB-231 breast cancer cell line. Asian Pac J Cancer Prev. 14:2983–2986. 2013. View Article : Google Scholar : PubMed/NCBI
21	Lyu X, Fang W, Cai L, Zheng H, Ye Y, Zhang L, Li J, Peng H, Cho WCS, Wang E, et al: TGFβR2 is a major target of miR-93 in nasopharyngeal carcinoma aggressiveness. Mol Cancer. 13:512014. View Article : Google Scholar : PubMed/NCBI
22	Poh YW, Gan SY and Tan EL: Effects of IL-6, IL-10 and TGF-β on the expression of survivin and apoptosis in nasopharyngeal carcinoma TW01 cells. Exp Oncol. 34:85–89. 2012.PubMed/NCBI
23	Niu G, Li B, Sun L and An C: MicroRNA-153 inhibits osteosarcoma cells proliferation and invasion by targeting TGF-β2. PLoS One. 10:e01192252015. View Article : Google Scholar : PubMed/NCBI
24	Liang C, Li X, Zhang L, Cui D, Quan X and Yang W: The anti-fibrotic effects of microRNA-153 by targeting TGFBR-2 in pulmonary fibrosis. Exp Mol Pathol. 99:279–285. 2015. View Article : Google Scholar : PubMed/NCBI